Valneva SE (VALN) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2024)
VALN's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
By Geography
VALN Revenue Analysis (2013–2024)
As of March 1, 2026, Valneva SE (VALN) generated trailing twelve-month (TTM) revenue of $196.3 million, reflecting exceptional growth of +27.0% year-over-year. The most recent quarter (Q2 2025) recorded $48.3 million in revenue, down 1.8% sequentially.
Looking at the longer-term picture, VALN's 5-year compound annual growth rate (CAGR) stands at +6.1%, indicating steady revenue expansion. The company achieved its highest annual revenue of $361.3 million in 2022.
Revenue diversification analysis shows VALN's business is primarily driven by IXIARO (59%), Third Party Products (21%), and DUKORAL (20%). With over half of revenue concentrated in IXIARO, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including BNTX (+3.7% YoY), MRNA (-56.1% YoY), and CDTX (-100.0% YoY), VALN has underperformed the peer group in terms of revenue growth. Compare VALN vs BNTX →
Peer Comparison
Compare VALN's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| VALNCurrent | $196M | +27.0% | +6.1% | 7.9% | |
| BNTX | $2.8B | +3.7% | +90.9% | -47.8% | |
| MRNA | $3.2B | -56.1% | +121.3% | -123.3% | |
| CDTX | $1M | -100.0% | -42.9% | -13811.9% | |
| SCNI | $658,000 | +303.9% | - | -1312.8% | |
| NVAX | $1.1B | +64.7% | +118.8% | 40.3% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $169.6M | +10.3% | $71.0M | 41.9% | $13.3M | 7.9% |
| 2023 | $153.7M | -57.5% | $52.8M | 34.4% | $-82,087,000 | -53.4% |
| 2022 | $361.3M | +3.8% | $36.9M | 10.2% | $-113,443,000 | -31.4% |
| 2021 | $348.1M | +215.5% | $160.2M | 46.0% | $-61,391,000 | -17.6% |
| 2020 | $110.3M | -12.6% | $56.0M | 50.8% | $-55,110,000 | -50.0% |
| 2019 | $126.2M | +11.6% | $76.2M | 60.4% | $-811,000 | -0.6% |
| 2018 | $113.0M | +7.4% | $69.6M | 61.6% | $6.3M | 5.5% |
| 2017 | $105.3M | +11.9% | $59.3M | 56.3% | $-3,954,000 | -3.8% |
| 2016 | $94.1M | +20.0% | $51.0M | 54.2% | $-42,568,000 | -45.3% |
| 2015 | $78.4M | +112.2% | $31.4M | 40.1% | $-19,934,000 | -25.4% |
See VALN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs VALN Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare VALN vs AGIO
See how VALN stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is VALN's revenue growth accelerating or slowing?
VALN revenue is accelerating at +27.0% year-over-year, exceeding the 5-year CAGR of +6.1%. TTM revenue reached $196M. Growth momentum has increased versus prior periods.
What is VALN's long-term revenue growth rate?
Valneva SE's 5-year revenue CAGR of +6.1% reflects the sustained expansion pattern. Current YoY growth of +27.0% is above this long-term average.
How is VALN's revenue distributed by segment?
VALN reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.